BALPHARMA vs KILITCH: Stock Comparison
KILITCH DRUGS INDIA is the larger company by market capitalisation. BALPHARMA shows a higher dividend yield and a higher ROCE, while KILITCH DRUGS INDIA shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BALPHARMA leads 2; KILITCH leads 7 of 11
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BALPHARMA | KILITCH |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BALPHARMA | KILITCH |
|---|---|---|
| Live Price | ₹106.79 | ₹202.11 |
| Day Change | 0.99% | -0.82% |
| Volume | 25,522 | 68,206 |
| 52-Week High | ₹124.6 | ₹439 |
| 52-Week Low | ₹60 | ₹117.25 |
| Distance from 52W High | -14.29% | -53.96% |
Valuation
| Metric | BALPHARMA | KILITCH |
|---|---|---|
| Market Cap | ₹134 Cr | ₹668 Cr |
| P/E Ratio | — | 26.1x |
| P/B Ratio | — | 2.81x |
| EPS | ₹0.71 | ₹0.83 |
| Book Value | ₹51.66 | ₹79.19 |
| Dividend Yield | 1.36% | 0% |
Growth
| Metric | BALPHARMA | KILITCH |
|---|---|---|
| Revenue Growth (TTM YoY) | 2.7% | 46.3% |
| EPS Growth (TTM YoY) | -33.5% | 26.5% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | BALPHARMA | KILITCH |
|---|---|---|
| ROE | 6.49% | 9.73% |
| ROCE | 9.07% | 7.73% |
| Net Margin | 2.02% | 12.81% |
| Operating Margin | 7.46% | 23.33% |
| Debt to Equity | 1.48x | 0.27x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | BALPHARMA | KILITCH |
|---|---|---|
| Promoter Holding | 46.74% | 63.77% |
| FII Holding | 0.28%▲ 0.13 pp | 0.11%▼ 0.01 pp |
| DII Holding | 0% | 0.5%▲ 0.5 pp |
| Public Holding | 48.87%▼ 0.12 pp | 35.62%▼ 0.49 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BALPHARMA and KILITCH DRUGS INDIA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.